Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
1.54 USD | -1.28% | 0.00% | +79.28% |
Kurzporträt
Mitarbeiterzahl: 138
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
David Woodhouse
CEO | Chief Executive Officer | 54 | 02.03.15 |
William Rieflin
CHM | Chairman | 64 | 01.09.10 |
Daniel Kaplan
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.08 |
William Chang
CTO | Chief Tech/Sci/R&D Officer | - | 01.02.19 |
Hsiao Lieu
CTO | Chief Tech/Sci/R&D Officer | 53 | 01.03.19 |
Valerie Pierce
CMP | Compliance Officer | 61 | 29.10.19 |
David Goeddel
BRD | Director/Board Member | 72 | 01.01.08 |
Joyce Q. Acbay
LAW | General Counsel | - | 01.04.20 |
Irene Perlich
AUD | Comptroller/Controller/Auditor | - | 01.03.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Roger Perlmutter
BRD | Director/Board Member | 71 | 08.06.21 |
David Goeddel
BRD | Director/Board Member | 72 | 01.01.08 |
William Rieflin
CHM | Chairman | 64 | 01.09.10 |
David Woodhouse
CEO | Chief Executive Officer | 54 | 02.03.15 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 83 462 408 | 81 886 322 ( 98,11 %) | 0 | 98,11 % |
Unternehmenskontakt
NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
94080-7014, South San Francisco
+650 243 5555
http://www.ngmbio.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+79.28% | 129 Mio. | |
-0.49% | 103 Mrd. | |
+3.31% | 96.73 Mrd. | |
+1.66% | 21.31 Mrd. | |
-16.16% | 21.21 Mrd. | |
-6.82% | 18.79 Mrd. | |
-41.41% | 16.37 Mrd. | |
-22.87% | 13.68 Mrd. | |
+6.32% | 13.44 Mrd. | |
+21.46% | 10.98 Mrd. |
- Börse
- Aktien
- A2N7B5 Aktie
- Unternehmen NGM Biopharmaceuticals, Inc.